autoimmune disease Archives -

Akili looks like it could bring another digital therapeutic (DTx) to market after a clinical trial backed the

Akili digital therapeutic shows promise in lupus patients

https://pharmaphorum.com/news/akili-digital-therapeutic-shows-promise-in-lupus-patients/

News/ News/ R&D

Pfizer and Roivant launch autoimmune specialist Priovant

Phil Taylor autoimmune disease, partnering, Pfizer, Priovant, Roivant 0 Comment

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to

Pfizer and Roivant launch autoimmune specialist Priovant

https://pharmaphorum.com/news/pfizer-and-roivant-launch-autoimmune-specialist-priovant/

News/ News/ R&D

AbbVie and Cugene partner to tackle autoimmune diseases

Joy Persaud AbbVie, autoimmune disease, immunology, pharma, R&D, Rinvoq 0 Comment

AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The

AbbVie and Cugene partner to tackle autoimmune diseases

https://pharmaphorum.com/news/abbvie-and-cugene-partner-to-tackle-autoimmune-diseases/

Events/ Events

3rd B & T Cell-Mediated Autoimmune Disease Drug Development Summit

Jessica Durston autoimmune, autoimmune disease, b cells, R&D, T-cells 0 Comment

Industry-led forum focused on B & T Cell Collaboration

3rd B & T Cell-Mediated Autoimmune Disease Drug Development Summit

https://pharmaphorum.com/events/3rd-b-t-cell-mediated-autoimmune-disease-drug-development-summit/

News/ News/ R&D

UCB chases after Argenx with FcRN drug for myasthenia gravis

Phil Taylor Argenx, autoimmune disease, efgartigimod, myasthenia gravis, rozanolixizumab, UCB 0 Comment

UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor

UCB chases after Argenx with FcRN drug for myasthenia gravis

https://pharmaphorum.com/news/ucb-chases-after-argenx-with-fcrn-drug-for-myasthenia-gravis/

Market Access/ News/ News

Flash FDA approval sends ChemoCentryx spiralling upwards

Phil Taylor autoimmune disease, avacopan, ChemoCentryx, fda, rare disease, regulatory approval, Tavneos 0 Comment

ChemoCentryx has claimed FDA approval for its avacopan drug for a rare autoimmune disease, becoming the first orally-active

Flash FDA approval sends ChemoCentryx spiralling upwards

https://pharmaphorum.com/news/flash-fda-approval-sends-chemocentryx-spiralling-upwards/

News/ News/ R&D

Lilly has a bad hair day as Pfizer rival hits the mark in alopecia

Phil Taylor alopecia, autoimmune disease, Concert Pharma, Eli Lilly, Incyte, JAK inhibitor, Pfizer 0 Comment

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer

Lilly has a bad hair day as Pfizer rival hits the mark in alopecia

https://pharmaphorum.com/news/lilly-has-a-bad-hair-day-as-pfizer-rival-hits-the-mark-in-alopecia/

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

Market Access/ News/ News

FDA sets September review date for Calliditas’ rare kidney disease drug

Phil Taylor autoimmune disease, Calliditas, fda, IGaN, kidney disease, nephrology, rare disease 0 Comment

Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA

FDA sets September review date for Calliditas’ rare kidney disease drug

https://pharmaphorum.com/news/fda-sets-september-review-date-for-calliditas-rare-kidney-disease-drug/

Market Access/ News/ News

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

Phil Taylor autoimmune disease, Calliditas, ema, kidney disease, nephrology, rare disease 0 Comment

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN),

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

https://pharmaphorum.com/news/calliditas-eyes-2022-approval-in-eu-for-rare-kidney-disease-drug-nefecon/

Trending

autoimmune disease

Login